These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35099823)

  • 1. Loss of STING expression is prognostic in non-small cell lung cancer.
    Lohinai Z; Dora D; Caldwell C; Rivard CJ; Suda K; Yu H; Rivalland G; Ellison K; Rozeboom L; Dziadziuszko R; Mitchell P; John T; Millan IS; Ren S; Hirsch FR
    J Surg Oncol; 2022 May; 125(6):1042-1052. PubMed ID: 35099823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and validation of the prognostic value of cyclic GMP-AMP synthase-stimulator of interferon (cGAS-STING) related genes in gastric cancer.
    Yang KS; Xu CQ; Lv J
    Bioengineered; 2021 Dec; 12(1):1238-1250. PubMed ID: 33843442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased activation of cGAS-STING pathway enhances radiosensitivity of non-small cell lung cancer cells.
    Xue A; Shang Y; Jiao P; Zhang S; Zhu C; He X; Feng G; Fan S
    Thorac Cancer; 2022 May; 13(9):1361-1368. PubMed ID: 35429143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non-small cell lung cancer.
    Gao Y; Zhang N; Zeng Z; Wu Q; Jiang X; Li S; Sun W; Zhang J; Li Y; Li J; He F; Huang Z; Zhang J; Gong Y; Xie C
    Clin Transl Med; 2022 Apr; 12(4):e792. PubMed ID: 35415876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of the crosstalk between YAP and cGAS-STING signaling in non-small cell lung cancer: it takes two to tango.
    Hao F
    Clin Transl Oncol; 2022 Sep; 24(9):1661-1672. PubMed ID: 35377059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rocaglamide promotes the infiltration and antitumor immunity of NK cells by activating cGAS-STING signaling in non-small cell lung cancer.
    Yan X; Yao C; Fang C; Han M; Gong C; Hu D; Shen W; Wang L; Li S; Zhu S
    Int J Biol Sci; 2022; 18(2):585-598. PubMed ID: 35002511
    [No Abstract]   [Full Text] [Related]  

  • 7. Entanglement of Methylation Changes and cGAS-STING Signaling in Non-Small-Cell Lung Cancer.
    Hao F
    Comb Chem High Throughput Screen; 2023; 26(1):224-235. PubMed ID: 35585823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
    Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
    Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 10.
    He XU; Yu Y; Zhang X; Gao C; Wang H; Liu C
    Cancer Genomics Proteomics; 2023; 20(5):476-486. PubMed ID: 37643778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of prognostic biomarkers and correlations with immune infiltrates among cGAS-STING in hepatocellular carcinoma.
    Qi Z; Yan F; Chen D; Xing W; Li Q; Zeng W; Bi B; Xie J
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33006365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer.
    Deng LL; Deng HB; Lu CL; Guo Y; Wang D; Yan CH; Lv X; Shao YX
    J Cancer Res Clin Oncol; 2014 Dec; 140(12):2097-105. PubMed ID: 24994038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. cGAS-STING Activation in the Tumor Microenvironment and Its Role in Cancer Immunity.
    Pépin G; Gantier MP
    Adv Exp Med Biol; 2017; 1024():175-194. PubMed ID: 28921470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
    Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
    Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
    Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
    Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases.
    Renaud S; Falcoz PE; Schaëffer M; Guenot D; Romain B; Olland A; Reeb J; Santelmo N; Chenard MP; Legrain M; Voegeli AC; Beau-Faller M; Massard G
    Br J Cancer; 2015 Oct; 113(8):1206-15. PubMed ID: 26372703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing.
    Rekhtman N; Brandt SM; Sigel CS; Friedlander MA; Riely GJ; Travis WD; Zakowski MF; Moreira AL
    J Thorac Oncol; 2011 Mar; 6(3):451-8. PubMed ID: 21266922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases.
    Mak KS; Gainor JF; Niemierko A; Oh KS; Willers H; Choi NC; Loeffler JS; Sequist LV; Shaw AT; Shih HA
    Neuro Oncol; 2015 Feb; 17(2):296-302. PubMed ID: 25053852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study.
    Cronin-Fenton D; Dalvi T; Movva N; Pedersen L; Hansen H; Fryzek J; Hedgeman E; Mellemgaard A; Rasmussen TR; Shire N; Hamilton-Dutoit S; Nørgaard M
    Sci Rep; 2021 Aug; 11(1):16892. PubMed ID: 34413420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
    Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
    Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.